Global Human Microbiome Immunology Therapeutics Market and Clinical Trial Insight 2025

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

"Global Human Microbiome Immunology Therapeutics Market and Clinical Trial Insight 2025" Report Highlights:

Global and Regional Market Insight
Global Human Microbiome Immunology Therapeutics Market: >US$ 1 Billion by 2025
US Dominates Global Market Landscape: >60% Market Share
Comprehensive Information on Ongoing clinical Trials and Potential Drug Candidates
Global Microbiome Modulator Drugs in Clinical Pipeline: >80 Drug in Trials
Therapeutic Applications of Microbiome Immunology by Indication
Clinical Trial Studies Related to Fecal Microbiota Transplant: > 250 Clinical Trials

The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology. The relevance that it has shown for the welfare of the society and pharmaceutical industry has led to the development of a transdisciplinary environment that is however conducive to innovation with a mission to abolish the limitations in the pharmaceutical industry through excellence in microbiome research, awareness and outreach. Over the years now, gut microbiome is estimated to implicate success for the various immunotherapies.

Microbiome’s role in immunology practices is to transform the world-class treatment into the medicine of today and tomorrow. It is highly recognizable that the healthcare issues that mankind is facing today is now bigger than any one solution. The treatment of certain diseases requires multiple options for the treatment and ultimately prevention. Therefore, the amalgamation of two different treatment paradigms i.e. microbiome and immunology are apparently delivering some medical benefits that millions of patients were in need for long period of time. The ways in which microbiome is understood and manipulated to serve the immunological aspects has given great interest to all the researchers.

Essential and usual concept of immunology depicts targeting the immune system of the body to provoke an immune response with huge impact but then unsuccessful implication of immunology therapies driven treatments led to exploration of several other basic concepts that could play an important role in boosting the immune system when combined. Looking forward, the microbiome community in the gut represented beneficial patterns with respect to further research. The area of microbiome research and its combination with immunological aspect for the disease treatment has produced a real excitement in the area of medical research and specifically microbiome research.

All over the world, the amalgamation of the two has been well accepted and appreciated by the patients, physicians and the clinicians. Investigation of all the working sides of microbiome and how it plays an important role in boosting the manipulated immune cells have recently started in large numbers as the technology available in the medical field allows to capture it accurately. To facilitate the microbiome and immunology community in order to extract the best and trending opportunities that are stemmed into the microbiome research, the experts from both the relevant disciplines are analyzing it through clinical researches and surveys. Further, the area is getting supported by 86 different clinical trials getting conducted in different countries.

"Global Human Microbiome Immunology Therapeutics Market and Clinical Trial Insight 2025" report summarizes the view of the wider opportunities that are associated microbiome community for the advancement of the scientific information regarding immunology. The science that is related with microbiome has high interdisciplinary and various opportunities that somehow have remained hidden in the medical world. It is believed that the opportunities and all the desirable tangible benefits microbiome is capable of delivering when combined with immunology is large and needs coordinated and constructive approach. The call to the two different sectors i.e. microbiology and immunology is estimated to unlock the potential and promising benefits of microbiome. The approach leading to the extraction of advantages if properly embedded in the microbiome and immunology research, the future benefits will be huge.

Overview of Microbiome

1.1 Introduction to Microbiome

1.2 History and Evolution of Microbiome

Role of Microbiome in Human Body

Microbiome: Various Forms

3.1 Gut Microbiome

3.2 Lung Microbiome

3.3 Skin Microbiome

3.4 Microbiome in Other Parts of the Body

Mechanism of Microbiome Activity

4.1 Nature of Immune Response

4.1.1 Immunosuppressive Activity

4.1.2 Immunostimulatory Activity

4.2 Messengers Involves in Microbiome Mechanism

4.2.1 MAMPs/PAMPs

4.2.2 Microbial Metabolites As Messengers

4.2.3 Host Cytokines As Messengers

4.2.4 Immune Cells As Messengers

Technological Requirement for Microbiota

5.1 Technologies Used

5.1.1 iChip

5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME)

5.1.3 Gut-on-a-Chip System

5.1.4 Colonic Stem Cell Construction

5.2 Harnessing and Engineering the Microbiome

5.2.1 Additive Approaches

5.2.2 Subtractive Approaches

Need for Microbiome Immunology

Therapeutic Applications of Microbiome Immunology

7.1 Microbiome Therapy

7.2 Precision Medicine

7.3 Drug discovery

7.4 Biomarkers and Therapy Optimization

Human Microbiota in Infectious Diseases

8.1 Infection with Clostridium Difficile

8.2 Infection with Helicobacter Pylori

8.3 Bacterial Vaginosis

8.4 Infection with HIV

The Human Microbiota and Liver Diseases

9.1 Non-Alcoholic Fatty Liver Disease (NAFLD)

9.2 Alcoholic Liver Diseases (ALD)

9.3 Liver Fibrosis and Cirrhosis

The Human Microbiota and Metabolic Disorders

10.1 Obesity

10.2 Type 2 Diabetes

The Human Microbiota and Other Diseases

11.1 Microbiota and Allergic Diseases

11.2 Microbiota and Psychiatric Diseases

Microbiome in Immuno Oncology

12.1 Role of Microbiome in Immuno Oncology

12.2 Microbiome Mechanism in Oncogenesis and Tumor Suppression

Microbiome Application by Cancer Types

13.1 Gastric Cancer

13.2 Colorectal Cancer

13.3 Esophageal Cancer

13.4 Hepatocellular Carcinoma

13.5 Melanoma

13.6 Solid Tumors

Industrial Approaches of Microbiome Therapy in Oncology

14.1 Bacterial Approaches

14.1.1 Fecal Microbiota Transplantation (FMT)

14.1.2 Synthetic Bacteria

14.1.3 Microbial Culture

14.2 Microbiome as Vaccine

14.3 Microbiome as Small Molecules

14.4 Microbiome Therapy using Phage Virus

Global Human Microbiome Market Analysis

15.1 Overview

15.2 Human Microbiome Market Segmentation

15.2.1 Regional Segmentation

15.2.2 Disease Based Segmentation

15.2.3 Segmentation by Application

Clinical Pipeline of Microbiome Based Therapy

16.1 Microbiome Modulators in Clinical Trial

16.2 Cancer Related Clinical Trials

16.2.1 Preclinical and Discovery Phase

16.2.2 Active Clinical Trials

16.3 Clinical Trial Related To FMT

16.3.1 Clinical Trial for Recurrent C. difficile

16.3.2 Clinical Trial for Inflammatory Bowel Disease (IBD)

16.3.3 Other FMT Related Clinical Trials

Global Microbiome Modulators Clinical Pipeline By Company, Indication and Phase

17.1 Research

17.2 Preclinical

17.3 Clinical

17.4 Phase-I

17.5 Phase-I/II

17.6 Phase-II

17.7 Phase-II/III

17.8 Phase-III

Marketed Microbiome Modulators Clinical Insight

18.1 Sodium Oligomannurarate - Shanghai Green Valley Pharmaceutical

18.2 Miya-BM

Global Microbiome Immunology Therapeutics Market Growth Drivers

Microbiome Technology - Investments, Acquisitions and Collaborations by Leading Microbiome Companies

Blockades in the Microbiome Immunology Market

21.1 Stable Engraftment

21.2 Development of Clinically Relevant Sensors

21.3 Robustness and Evolutionary Stability of Genetic Circuits

21.4 Regulation, Safety and Biocontainment

Global Microbiome Immunology Market Future Panorama

Competitive Landscape

23.1 4D Pharma

23.2 AbbVie

23.3 AstraZeneca plc

23.4 Biocodex

23.5 Bristol Mayer Squibb

23.6 Corebiome/Diversigen

23.7 Elogi Bioscience

23.8 Enterome

23.9 Ferring Pharmaceuticals

23.10 Finch Therapeutics

23.11 Maat Pharma

23.12 Merck

23.13 Microbiome Therapeutics

23.14 Novartis

23.15 OpenBiome

23.16 Pfizer

23.17 Rebiotix

23.18 Second Genome

23.19 Seres Therapeutics

23.20 Symberix

23.21 Takeda Pharmaceuticals

23.22 Vedanta Bioscience

Figure 1-1: Microbiome Found in Our Body

Figure 1-2: Evolution of Microbiome in Medicinal Use

Figure 2-1: Composition of Human Microbiota

Figure 2-2: Roles of Microbiome in Human Body

Figure 3-1: Different Types of Human Microbiome

Figure 3-2: Factors Affecting the Development of the Gut Microbiome in Humans

Figure 3-3: Study Linking Gut Microbiota and Food Sensitization at 1 year of Age, 2015

Figure 4-1: Steps in Mechanism of Microbiome

Figure 4-2: Types of Immune Response Produced by Microbiome

Figure 4-3: Mechanism of Immunosuppressive Activity of Microbiome

Figure 4-4: Processes Facilitating Immunostimulatory Effect of the Gut Microbiota

Figure 4-5: Immunostimulatory Action of Microbiome by Increasing the Antigenicity

Figure 4-6: Immunostimulatory Action of Microbiome via Adjuvanticity

Figure 4-7: Immunostimulatory Action of Microbiome via Bystander T-cell Activation

Figure 4-8: Messengers Involved in Mechanism of Microbiome Activity

Figure 5-1: Technologies Used in Microbiota Immunotherapy

Figure 5-2: New Methods for In-Vitro Simulation of Microbes

Figure 5-3: Approaches in Harnessing and Engineering the Microbiome

Figure 7-1: Therapeutic Applications of Microbiome

Figure 8-1: Impact of Infectious Diseases in Human Microbiota

Figure 8-2: Microbiome Imbalance Related Infections

Figure 8-3: Mechanism of Microbiome against H. pylori Infection

Figure 8-4: Management of H. pylori Infection using Single and Multi Strain Probiotic Microbiome

Figure 8-5: Process of Vaginal Microbiota Transplantation (VMT)

Figure 8-6: Mechanism of Different Microbiome therapeutics against HIV infection

Figure 9-1: Hypothetical Pathway: Role of Gut Microbiota Dysbiosis in Liver Diseases

Figure 9-2: Microbiome Related Liver Disorders

Figure 9-3: Management of Non-Alcoholic Fatty Liver Disease using Probiotic Microbiome

Figure 9-4: Management of Alcoholic Liver Disease using Probiotic Microbiome

Figure 9-5: Management of Liver Fibrosis and Cirrhosis using Probiotic Microbiome

Figure 10-1: Metabolic Disorders Related to Gut Microbiota

Figure 10-2: Relation of Microbiome with the Metabolic Disorders

Figure 10-3: Factors Responsible for Obesity

Figure 10-4: Mechanism of Probiotics against Obesity

Figure 10-5: Management of Obesity using Probiotic Microbiome

Figure 10-6: Influence of Disturbed Gut Microbiome on Diabetes

Figure 10-7: Management of Type 2 Diabetes using Probiotic Microbiome

Figure 11-1: Allergic Diseases Influenced by Microbiome

Figure 11-2: Management of Allergic Diseases using Microbiome Preparations

Figure 11-3: Microbiome Associated Psychiatric Disorders

Figure 11-4: Management of Psychiatric Disorders using Microbiome

Figure 12-1: Microbiome at the Intersection between Physiology and Pathology in Cancer

Figure 12-2: Microbiome Action in Tumor Formation vs. Tumor Suppression

Figure 13-1: Microbiome Applications on Basis of Cancer Types

Figure 13-2: Management of Colorectal Cancer using Microbiomes

Figure 13-3: Anticancer Mechanism of Microbiome Metabolite (Butyrate)

Figure 13-4: Microbiome of Normal Esophagus vs. GERD-Barrett’s Esophagus

Figure 13-5: Management of Esophageal Cancer using Microbiome

Figure 13-6: Role of Disturbed Microbiome in Development of Hepatocellular Carcinoma

Figure 14-1: Industrial Approaches of Microbiome Therapy in Oncology

Figure 14-2: Number of Companies Involved in Different Anticancer Approaches of Microbiome, 2019

Figure 14-3: Companies Involved in Different Anticancer Approaches of Microbiome (%), 2019

Figure 14-4: Types of Bacterial Approaches in Microbiome Technology

Figure 14-5: Number of Companies Involved in Different Bacterial Approaches, 2019

Figure 14-6: Procedure of Fecal Microbiota Transplantation (FMT)

Figure 14-7: Various Engineered Circuits of Synthetic Bacteria

Figure 14-8: Applications of Phage in Cancer Biology and Treatment

Figure 15-1: Global – Human Microbiome Market Size (US$ Million), 2018 to 2025

Figure 15-2: Global – Human Microbiome Market Size and FMT Market Size (US$ Million), 2019

Figure 15-3: Global - Human Microbiome Market Segmentation

Figure 15-4: Global - Microbiome Therapeutic Market Share (%) – US,Europe and Rest of World, 2019 and 2025

Figure 15-5: USA – Human Microbiome Market Size (US$ Million), 2019 and 2025

Figure 15-6: Europe – Human Microbiome Market Size (US$ Million), 2019 and 2025

Figure 15-7: Global – Human Microbiome Market Share by Diseases (%), 2025

Figure 15-8: Global - Human Microbiome Market by Application (%), 2019 and 2025

Figure 16-1: Global - Microbiome Modulator Drug Clinical Pipeline by Phase, 2020

Figure 16-2: Global - Microbiome Modulator Drug Clinical Pipeline by Country, 2020

Figure 16-3: Global - Microbiome Modulator Drug Clinical Pipeline by Drug Class, 2020

Figure 16-4: Global - Microbiome Modulator Drug Clinical Pipeline by Drug Company, 2020

Figure 16-5: Global - Microbiome Modulator Drug Clinical Pipeline by Indication, 2020

Figure 16-6: Number of Microbiome-Based Cancer Therapeutics in Discovery and Preclinical Phase of Development, 2019

Figure 16-7: Companies Conducting Discovery Program of Anticancer Microbiome

Figure 16-8: Companies Conducting Preclinical Trials of Anticancer Microbiome

Figure 16-9: Active Clinical Trials of Anticancer Microbiome

Figure 16-10: Global - Number of Clinical Trial Studies Related to Fecal Microbiota Transplant in Different Phases,2020

Figure 16-11: Global - Fecal Microbiota Transplant in Different Phases of Clinical Trial (%), 2020

Figure 16-12: Global - Status of Active FMT Clinical Trials, 2020

Figure 16-13: Global - FMT Clinical Trial in Management of C. difficile Infection, 2020

Figure 16-14: Global - FMT Clinical Trial in Management of Inflammatory bowel Disease, 2020

Figure 19-1: Drivers of Microbiome Immunotherapeutics

Figure 20-1: MaaT Pharma – Investment Received by Year (EUR/US$ Million), 2015, 2016 and 2020

Figure 20-2: Finch Therapeutics – Investments Received by Year (US$ Million), 2016 - 2019

Figure 20-3: Rebiotix – Investment Received by Year (US$ Million), 2011, 2014 and 2017

Figure 20-4: Enterome – Investment Received by Year (EUR/US$ Million), 2011,2012, 2014, 2016, 2017 and 2020

Figure 20-5: Second Genome – Investments by Year (US$ Million), 2011, 2013 and 2016

Figure 21-1: Challenges in the Path of Microbiome Immunotherapy Technology

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global Human Microbiome Immunology Therapeutics Market and Clinical Trial Insight 2025

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

"Global Human Microbiome Immunology Therapeutics Market and Clinical Trial Insight 2025" Report Highlights:

Global and Regional Market Insight

Global Human Microbiome Immunology Therapeutics Market: >US$ 1 Billion by 2025

US Dominates Global Market Landscape: >60% Market Share

Comprehensive Information on Ongoing clinical Trials and Potential Drug Candidates

Global Microbiome Modulator Drugs in Clinical Pipeline: >80 Drug in Trials

Therapeutic Applications of Microbiome Immunology by Indication

Clinical Trial Studies Related to Fecal Microbiota Transplant: > 250 Clinical Trials

Overview of Microbiome

1.1 Introduction to Microbiome

1.2 History and Evolution of Microbiome

Role of Microbiome in Human Body

Microbiome: Various Forms

3.1 Gut Microbiome

3.2 Lung Microbiome

3.3 Skin Microbiome

3.4 Microbiome in Other Parts of the Body

Mechanism of Microbiome Activity

4.1 Nature of Immune Response

4.1.1 Immunosuppressive Activity

4.1.2 Immunostimulatory Activity

4.2 Messengers Involves in Microbiome Mechanism

4.2.1 MAMPs/PAMPs

4.2.2 Microbial Metabolites As Messengers

4.2.3 Host Cytokines As Messengers

4.2.4 Immune Cells As Messengers

Technological Requirement for Microbiota

5.1 Technologies Used

5.1.1 iChip

5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME)

5.1.3 Gut-on-a-Chip System

5.1.4 Colonic Stem Cell Construction

5.2 Harnessing and Engineering the Microbiome

5.2.1 Additive Approaches

5.2.2 Subtractive Approaches

Need for Microbiome Immunology

Therapeutic Applications of Microbiome Immunology

7.1 Microbiome Therapy

7.2 Precision Medicine

7.3 Drug discovery

7.4 Biomarkers and Therapy Optimization

Human Microbiota in Infectious Diseases

8.1 Infection with Clostridium Difficile

8.2 Infection with Helicobacter Pylori

8.3 Bacterial Vaginosis

8.4 Infection with HIV

The Human Microbiota and Liver Diseases

9.1 Non-Alcoholic Fatty Liver Disease (NAFLD)

9.2 Alcoholic Liver Diseases (ALD)

9.3 Liver Fibrosis and Cirrhosis

The Human Microbiota and Metabolic Disorders

10.1 Obesity

10.2 Type 2 Diabetes

The Human Microbiota and Other Diseases

11.1 Microbiota and Allergic Diseases

11.2 Microbiota and Psychiatric Diseases

Microbiome in Immuno Oncology

12.1 Role of Microbiome in Immuno Oncology

12.2 Microbiome Mechanism in Oncogenesis and Tumor Suppression

Microbiome Application by Cancer Types

13.1 Gastric Cancer

13.2 Colorectal Cancer

13.3 Esophageal Cancer

13.4 Hepatocellular Carcinoma

13.5 Melanoma

13.6 Solid Tumors

Industrial Approaches of Microbiome Therapy in Oncology

14.1 Bacterial Approaches

14.1.1 Fecal Microbiota Transplantation (FMT)

14.1.2 Synthetic Bacteria

14.1.3 Microbial Culture

14.2 Microbiome as Vaccine

14.3 Microbiome as Small Molecules

14.4 Microbiome Therapy using Phage Virus

Global Human Microbiome Market Analysis

15.1 Overview

15.2 Human Microbiome Market Segmentation

15.2.1 Regional Segmentation